Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: Design, Development, and Place in Therapy

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s172512
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients With Chronic Hepatitis C Infection

Advances in Therapy
MedicinePharmacology
2020English

Glecaprevir and Pibrentasvir Combination Therapy for Hepatitis C Virus-Infected Japanese Patients on Hemodialysis

Renal Replacement Therapy
2018English

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy

Gastroenterology
HepatologyGastroenterology
2019English

Glecaprevir/Pibrentasvir for 8 Weeks in Treatment-Naïve Patients With Chronic HCV Genotypes 1–6 and Compensated Cirrhosis: The EXPEDITION-8 Trial

Journal of Hepatology
Hepatology
2020English

Obinutuzumab in Chronic Lymphocytic Leukemia: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Historical Treatment of Chronic Hepatitis B and Chronic Hepatitis C.

Gut
Gastroenterology
1993English

Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Recent Advances in Antiviral Therapy for Chronic Hepatitis C

Mediators of Inflammation
ImmunologyCell Biology
2016English

Osimertinib in the Treatment of Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Lung Cancer: Targets and Therapy
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy